Corcept Therapeutics

YTD

ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.

CEO

Joseph K. Belanoff

CEOJoseph K. Belanoff

Employees

730

Employees730

Headquarters

Redwood City, California

HeadquartersRedwood City, California

Founded

1998

Founded1998

Employees

730

Employees730

CORT Key Statistics

Market cap

6.13B

Market cap6.13B

Price-Earnings ratio

146.17

Price-Earnings ratio146.17

Dividend yield

—

Dividend yield—

Average volume

1.39M

Average volume1.39M

High today

$57.98

High today$57.98

Low today

$51.85

Low today$51.85

Open price

$53.74

Open price$53.74

Volume

2.31M

Volume2.31M

52 Week high

$91.00

52 Week high$91.00

52 Week low

$28.66

52 Week low$28.66

Stock Snapshot

As of today, Corcept Therapeutics(CORT) shares are valued at $56.70. The company's market cap stands at 6.13B, with a P/E ratio of 146.17.

As of 2026-05-13, Corcept Therapeutics(CORT) stock has fluctuated between $51.85 and $57.98. The current price stands at $56.70, placing the stock +9.4% above today's low and -2.2% off the high.

Corcept Therapeutics(CORT) shares are trading with a volume of 2.31M, against a daily average of 1.39M.

During the past year, Corcept Therapeutics(CORT) stock moved between $28.66 at its lowest and $91.00 at its peak.

CORT News

Seeking Alpha 6h

Corcept Therapeutics climbs on UBS upgrade

Corcept Therapeutics (CORT) jumped more than 7% on Wednesday after the stock was upgraded to Buy from Neutral by UBS Group. The brokerage firm also raised its...

TipRanks 8h

Corcept Therapeutics upgraded to Buy from Neutral at UBS

UBS upgraded Corcept Therapeutics (CORT) to Buy from Neutral with a price target of $72, up from $44. The recent approval of Lifyorli in ovarian cancer is expec...

Simply Wall St 4d

Corcept’s ALS Survival Signal Reframes Cortisol Modulation And Growth Outlook

Corcept Therapeutics reported long term survival data from its DAZALS Phase 2 trial of dazucorilant in ALS. Patients receiving 300 mg daily experienced an 87%...

Analyst ratings

83%

of 6 ratings

Buy

83.3%

Hold

16.7%

Sell

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Novo Nordisk

Broadcom

Palantir Technologies

Robinhood Markets

Spotify

Gilead Sciences

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.